Literature DB >> 15353272

Laboratory diagnostic aspects of drug resistant tuberculosis.

Linda M Parsons1, Akos Somoskövi, Richard Urbanczik, Max Salfinger.   

Abstract

Multi-drug resistant strains of Mycobacterium tuberculosis (MDR-TB) are present world wide, and in many areas constitute a serious threat to the efficacy of TB control programs. The most effective strategies to limit further spread of MDR-TB are rapid detection of drug resistance followed by prompt and effective therapy. Routine laboratory diagnosis of drug resistance in TB requires a viable, pure culture of M. tuberculosis. Use of liquid media has decreased the turn around time for susceptibility test results however, because of the slow growth of M. tuberculosis these assays can still take 10 to 14 days. Alternatively, an increased understanding of the molecular basis for resistance to the antituberculosis drugs can greatly contribute to further decreasing turn around time. Based on this information, more precise and rapid molecular testing can be developed and lead to more appropriate and timely treatment regimens. In this review, we discuss methods for, and problems encountered in, performing TB drug susceptibility assays. Descriptions of routine protocols will be followed by recent developments in molecular detection of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353272     DOI: 10.2741/1290

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  22 in total

1.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

2.  Evaluation of methods for rapid detection of resistance to isoniazid and rifampin in Mycobacterium tuberculosis isolates collected in the Caribbean.

Authors:  Patrick Eberechi Akpaka; Shirematee Baboolal; Denise Clarke; Lorraine Francis; Nalin Rastogi
Journal:  J Clin Microbiol       Date:  2008-08-13       Impact factor: 5.948

3.  Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Pamela Chedore; Lina Bertucci; Joyce Wolfe; Meenu Sharma; Frances Jamieson
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

4.  Sensitivity to isoniazid of Mycobacterium bovis BCG strains and BCG disseminated disease isolates.

Authors:  Kristopher Kolibab; Steven C Derrick; Sheldon L Morris
Journal:  J Clin Microbiol       Date:  2011-04-20       Impact factor: 5.948

5.  Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France.

Authors:  Florence Brossier; Wladimir Sougakoff; Christine Bernard; Matthieu Petrou; Karine Adeyema; Anne Pham; Diane Amy de la Breteque; Marine Vallet; Vincent Jarlier; Christophe Sola; Nicolas Veziris
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

6.  Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates.

Authors:  Doris Hillemann; Michael Weizenegger; Tanja Kubica; Elvira Richter; Stefan Niemann
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 7.  Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities.

Authors:  Linda M Parsons; Akos Somoskövi; Cristina Gutierrez; Evan Lee; C N Paramasivan; Alash'le Abimiku; Steven Spector; Giorgio Roscigno; John Nkengasong
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

8.  Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates.

Authors:  Claudia Plinke; Sabine Rüsch-Gerdes; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

9.  Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo.

Authors:  Claudia Plinke; Kerstin Walter; Sahar Aly; Stefan Ehlers; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

10.  Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis.

Authors:  Miguel Viveiros; Clara Leandro; Liliana Rodrigues; Josefina Almeida; Rosário Bettencourt; Isabel Couto; Lurdes Carrilho; José Diogo; Ana Fonseca; Luís Lito; João Lopes; Teresa Pacheco; Mariana Pessanha; Judite Quirim; Luísa Sancho; Max Salfinger; Leonard Amaral
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.